This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Prescribing Information for NGENLA▼(somatrogon) can be found here. Prescribing Information for Genotropin (somatropin) can be found here. Adverse event reporting information can be found at the bottom of the page.
The recommended dose is 0.66 mg/kg bodyweight administered once weekly by subcutaneous injection.
| 24mg Pen(20mg/ml) | 60mg Pen(50mg/ml) |
|---|---|
| Suggested for doses less than 12mg (bodyweight < 18kg) Dose increments of 0.2mg |
Suggested for doses 12mg and above (bodyweight 18kg and over) Doses > 30mg (ie. bodyweight > 45kg), two injections are needed. Dose increments of 0.5mg |
Each prefilled pen is capable of setting and delivering the dose prescribed by the physician. Dose may be rounded up or down based on the physician's expert knowledge of the individual patient needs.
Based on growth velocity, adverse reactions, body weight and serum insulin-like growth factor 1(IGF-1) concentrations. Note: When monitoring IGF-1, samples should always be drawn 4 days after prior dose.
For full dosing details, refer to the Summary of Product Characteristics for NGENLA.
| Before first use | After first use |
|---|---|
| Prior to the first use, NGENLA may be stored for 3 years at 2–8°C in a refrigerator. The unopened pre-filled pen may temporarily be held for up to 4 hours at temperatures up to 32 °C. |
After first use, NGENLA may be stored for 28 days in a refrigerator (2 °C – 8 °C). NGENLA may be held at room temperature (up to 32°C) for up to 4 hours with each injection for a maximum of 5 times. Return NGENLA to the refrigerator again after each use. It should not be frozen and should be stored with the pen cap attached in order to protect from light. |
Refer to the Summary of Product Characteristics for NGENLA for full storage information.
NGENLA is administered by a pre-filled, multi-dose, disposable pen – giving patients and caregivers the confidence to administer treatment and get back to moments that matter.
NGENLA is to be injected in the abdomen, thighs, buttocks or upper arms. The site of injection should be rotated at each administration. Injections to the upper arms and buttocks should be given by the caregiver.
Sterile needles are required for administration but are not included in the NGENLA pack.
NGENLA can be administered with a needle from 4mm to 8mm and 31G or 32G.
Pfizer will provide a box of needles as standard within the patient starter box:
- BD Micro-Fine Ultra 5mm 32G needles (quantity 100)
For resupply, or to order additional or different needles at no cost, the patient/caregiver or Healthcare Professional can contact the Endocrine Helpline on 0800 521249 or [email protected]
View the video below for guidance on how NGENLA is prepared and administered.
Needles with a safety shield have been approved for use with NGENLA in Northern Ireland1. Needles with a safety shield do not have an inner needle cap. If in Northern Ireland and using a needle with a safety shield, refer to the manufacturer’s instructions for use when attaching and removing the needle2,3.
For full instructions on how to use the NGENLA pen see the PIL for Northern Ireland and
PIL for Great Britain.
Access PIP Codes and key details on how to order NGENLA for your patients.
Access practical support for initiating patients on NGENLA and learn more about how NGENLA may deliver a treatment experience favoured by patients and caregivers.4
References:
Find out information about the starter kits available to patients starting treatment with NGENLA.
Download the document to access information supporting fomulary application for NGENLA.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024